X4 Pharmaceuticals, Inc: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 8, 2024 and accepted by EDGAR at Aug 8, 2024, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $700.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $700.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $268.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $268.0k | us-gaap:CostOfRevenue |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $20.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $40.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | $71.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | $33.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $2.2m | us-gaap:InterestExpense |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $4.0m | us-gaap:InterestExpense |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $18.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | $37.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $90.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | $39.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | $0.45 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | $0.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $0.45 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | $0.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 200,801,311 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 200,455,883 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-04-01 to 2024-06-30 | −$63.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$63.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $193.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2024-06-30 | $147.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $175.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $210.6m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $28.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $116.2m | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $75.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2024-06-30 | $94.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-24-036127. Last ingested by Listed: Nov 4, 2026, 16:53 ET. Listed shows no prices and gives no investment advice.